Loading...
Loading...
Contributors:
Dataset URI:
f1ac1683-3050-4fe5-b91f-ea9c4c762eb7The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response or intolerance to MTX, as measured by the American College of Rheumatology (ACR) 20 response rate at Week 24.This study will also evaluate the pharmacokinetics and safety of ASP015K as well as efficacy and safety of long-term treatment with ASP015K (52 weeks).
Keyword(s):
Disease-modifying antirheumatic drugs (DMARDs); Peficitinib; Plaebo; Rheumatoid Arthritis; Rheumatoid Arthritis (RA).
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
No Associated Publication Data Available
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)